Key Summary: On November 14, 2023, Moshe Arkin (10%) urged the Board to prioritize Lonafarnib's potential for treating Hepatitis Delta Virus (HDV), proposing a new drug application and financing through a private offering with major shareholders. He suggested adding investor representatives to the Board to boost the stock price and aimed to collaborate for maximizing shareholder value.Market Cap: $14 million | Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
On November 14, 2023, Moshe Arkin (10%) urged the Board to focus on Lonafarnib's potential as a treatment for Hepatitis Delta Virus (HDV). He proposed filing a new drug application for Lonafarnib, financing it through a private offering with major shareholders, and placing investor representatives on the Board to enhance the stock price. Moshe Arkin aimed to collaborate with management and the Board to maximize shareholder value. Source
On December 4, 2023, Moshe Arkin reiterated his concerns.
Kommentare